VC dollars pour into biopharma, with Q2 haul signaling sunshine ahead

With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally.

Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank.